Strategy's 15min chart signals bullish trend with KDJ Golden Cross and Bullish Marubozu

Our 15-minute chart analysis has identified a significant technical indicator, the KDJ Golden Cross, which occurred at 14:45 on August 21, 2025. This event, coupled with the presence of a Bullish Marubozu candlestick pattern, suggests a shift in market momentum towards an upward trajectory. This trend is likely to persist, as the dominant buying activity indicates control of the market by buyers. Consequently, we anticipate continued bullish momentum in the stock price.

The U.S. healthcare sector has emerged as a strong investment opportunity in the second quarter of 2025, driven by a rare alignment of technical and fundamental signals. Key players such as Cosmos Health and HCA Healthcare reported robust revenue growth, while technical indicators like the KDJ Golden Cross and Bullish Marubozu patterns suggest short-term bullish momentum. This article explores these developments and contrasts them with the overvalued momentum in the energy sector.

Fundamental Momentum: Healthcare's Resilient Growth

The second quarter of 2025 delivered impressive results for healthcare companies. Cosmos Health Inc. reported a 11.66% year-over-year revenue increase to $14.75 million, alongside a 51.60% surge in gross profit. HCA Healthcare, a $18.6 billion revenue giant, saw a 13.1% jump in net income to $1.653 billion, driven by 1.8% growth in same-facility admissions and 4.0% higher revenue per admission [1].

These results reflect the sector's resilience amid macroeconomic headwinds, fueled by aging demographics, AI-driven operational efficiency, and expanding outpatient care models. The broader healthcare landscape is equally promising, with locum tenens staffing growing 15% in 2024 and projected to rise 6% in 2025, while digital health M&A surged, with Teladoc Health acquiring UpLift and Transcarent merging with Accolade [1].

Technical Convergence: Golden Crosses and Marubozu Patterns

Technical analysis in Q2 2025 highlighted bullish momentum in healthcare equities. For example, Fulgent Genetics (NASDAQ: FLGT) triggered a KDJ Golden Cross and Bullish Marubozu on its 15-minute chart on August 18, 2022, signaling a shift in buyer dominance. This pattern coincided with a 15% year-over-year revenue increase and a revised full-year guidance of $320 million in core revenue [1]. Similarly, Healthstream (HLSTRM) displayed a KDJ Golden Cross and Marubozu on August 13, 2025, aligning with a 29.3% surge in net income and 4.0% revenue growth [1].

The Bullish Marubozu—a candlestick with no lower wick and a long upper wick—indicates strong buying pressure and lack of seller resistance. When combined with the KDJ Golden Cross (short-term K line crossing above long-term D line), these signals suggest a high probability of continued upward movement. For instance, Optimizerx (OPTXRX) triggered a similar pattern on August 15, 2025, despite limited Q2 sales data, as its consistent earnings beats and AI-driven solutions attracted institutional attention [1].

Contrasting Energy's Overvalued Momentum

While energy stocks have benefited from geopolitical volatility and inflation-linked demand, their valuations are increasingly stretched. Oil majors like ExxonMobil (XOM) and Chevron (CVX) trade at elevated price-to-earnings ratios, reflecting market optimism about sustained high prices. However, renewable energy and electric vehicle (EV) stocks face headwinds from regulatory uncertainty and supply chain bottlenecks [1].

In contrast, healthcare's undervalued momentum is supported by diverse growth drivers. The sector's 7% EBITDA CAGR from 2023 to 2028 (projected to reach $987 billion) is underpinned by non-acute care expansion, specialty pharmacy growth, and digital transformation. Unlike energy, healthcare is less exposed to commodity price swings and more insulated by demographic tailwinds and technological innovation [1].

Investment Thesis: Buy at the Confluence

The convergence of technical and fundamental signals in healthcare equities presents a compelling entry point. Key considerations include:
1. KDJ Golden Cross + Bullish Marubozu: These patterns, observed in stocks like Fulgent Genetics and Healthstream, indicate short-term bullish momentum.
2. Revenue Growth: Companies like HCA Healthcare and Cosmos Health demonstrate sustainable top-line expansion, supported by operational efficiency and strategic acquisitions.
3. Sector Resilience: Healthcare's diversified demand drivers (aging population, AI adoption, outpatient care) make it less cyclical than energy.

Risks and Cautions

While the case for healthcare is strong, investors should remain cautious about regulatory risks (e.g., the Inflation Reduction Act's impact on drug pricing) and valuation extremes in subsectors like telehealth. However, the sector's strong balance sheets (e.g., HCA Healthcare's $61.84 million in total assets) and dividend yields (e.g., Healthstream's Q3 2025 dividend of $0.14/share) provide a margin of safety [1].

Conclusion: A Golden Cross for Healthcare

The healthcare sector in Q2 2025 is at a critical inflection point, where technical bullishness and fundamental strength align to create a strong buy opportunity. As energy stocks face valuation pressures and macroeconomic uncertainties, healthcare's diversified growth drivers and innovation-led momentum position it as a superior long-term investment. For investors seeking asymmetric upside, the confluence of KDJ Golden Crosses, Bullish Marubozu patterns, and surging sales in healthcare equities offers a compelling case to act—now.

References:
[1] https://www.ainvest.com/news/american-healthcare-golden-cross-rising-sales-signal-strong-buy-opportunity-2508/